{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
mavacamten
to a specific field?
There is one exact (name or code) match for mavacamten
Status:
US Approved Rx
(2022)
Source:
NDA214998
(2022)
Source URL:
First approved in 2022
Source:
NDA214998
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
MYK-461 (also known as Mavacamten) is a small-molecule modulator of cardiac myosin that targets the underlying sarcomere hypercontractility of hypertrophic cardiomyopathy, one of the most prevalent heritable cardiovascular disorders. Studies on isolated cells and muscle fibers, as well as intact animals, have shown that MYK-461 inhibits sarcomere force production, thereby reducing cardiac contractility. In Phase II clinical trials MYK-461 reduces left ventricular outflow tract obstruction and improve exercise capacity and symptoms in patients with obstructive hypertrophic cardiomyopathy. Phase III clinical trials are currently ongoing.
Showing 1 - 1 of 1 results
Status:
US Approved Rx
(2022)
Source:
NDA214998
(2022)
Source URL:
First approved in 2022
Source:
NDA214998
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
MYK-461 (also known as Mavacamten) is a small-molecule modulator of cardiac myosin that targets the underlying sarcomere hypercontractility of hypertrophic cardiomyopathy, one of the most prevalent heritable cardiovascular disorders. Studies on isolated cells and muscle fibers, as well as intact animals, have shown that MYK-461 inhibits sarcomere force production, thereby reducing cardiac contractility. In Phase II clinical trials MYK-461 reduces left ventricular outflow tract obstruction and improve exercise capacity and symptoms in patients with obstructive hypertrophic cardiomyopathy. Phase III clinical trials are currently ongoing.
